Correction to: Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications (Journal of Experimental & Clinical Cancer Research, (2025), 44, 1, (139), 10.1186/s13046-025-03386-8) - Details

author：

Indexed by：

Scopus

Abstract：

Correction:　J　Exp　Clin　Cancer　Res　44,　139　(2025)　Following　the　publication　of　the　original　article　[1],　the　authors　identified　an　identical　images　mistakenly　used　in　Fig. 3A　and　B.　The　figure　figure　is　presented　below:　PDGFRA　inhibitor　avapritinib　sensitizes　HCC　cells　to　lenvatinib　treatment.　(A)　The　effect　of　lenvatinib　and　avapritinib　was　tested　in　the　colonyformation　assay　in　SMMC-7721-LR　and　SNU-449-LR　cells.　(B)　Synergistic　response　to　the　combination　of　lenvatinib　and　avapritinib　in　PDGFRA　high　C3A　and　SNU-398　cells　and　in　PDGFRA　low　SMMC-7721　and　SNU-449　cells.　(C)　Representative　tumor　images　of　each　group　of　SMMC-7721-LR　xenografts　at　the　end　of　lenvatinib,　avapritinib　or　combination　treatment.　(D)　Tumor　growth　curves　and　tumor　weight　of　each　group　are　shown.　(E)　Representative　H&E　staining,　IHC　images　of　PDGFRA　and　Ki67　in　subcutaneous　implantation　mouse　model.　(F)　Representative　tumor　images　of　each　group　of　PDGFRA　overexpressing　SMMC-7721　xenografts　at　the　end　of　lenvatinib,　avapritinib　or　combination　treatment.　(G)　Tumor　growth　curve　and　tumor　weight　of　each　group　(H)　Representative　H&E　staining,　IHC　images　of　PDGFRA　and　Ki67　in　subcutaneous　implantation　mouse　model　PDGFRA　inhibitor　avapritinib　sensitizes　HCC　cells　to　lenvatinib　treatment.　(A)　The　effect　of　lenvatinib　and　avapritinib　was　tested　in　the　colonyformation　assay　in　SMMC-7721-LR　and　SNU-449-LR　cells.　(B)　Synergistic　response　to　the　combination　of　lenvatinib　and　avapritinib　in　PDGFRA　high　C3A　and　SNU-398　cells　and　in　PDGFRA　low　SMMC-7721　and　SNU-449　cells.　(C)　Representative　tumor　images　of　each　group　of　SMMC-7721-LR　xenografts　at　the　end　of　lenvatinib,　avapritinib　or　combination　treatment.　(D)　Tumor　growth　curves　and　tumor　weight　of　each　group　are　shown.　(E)　Representative　H&E　staining,　IHC　images　of　PDGFRA　and　Ki67　in　subcutaneous　implantation　mouse　model.　(F)　Representative　tumor　images　of　each　group　of　PDGFRA　overexpressing　SMMC-7721　xenografts　at　the　end　of　lenvatinib,　avapritinib　or　combination　treatment.　(G)　Tumor　growth　curve　and　tumor　weight　of　each　group　(H)　Representative　H&E　staining,　IHC　images　of　PDGFRA　and　Ki67　in　subcutaneous　implantation　mouse　model　The　correction　does　not　compromise　the　validity　of　the　conclusions　and　the　overall　content　of　the　article.　The　original　article　[1]　has　been　updated.　©　The　Author(s)　2025.

Keyword：

Community：

[ 1 ] [Zhao B.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 2 ] [Zhao B.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 3 ] [Zhou Y.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 4 ] [Zhou Y.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 5 ] [Cheng N.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 6 ] [Cheng N.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 7 ] [Zheng X.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 8 ] [Zheng X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 9 ] [Chen G.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 10 ] [Chen G.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 11 ] [Qi X.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 12 ] [Qi X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 13 ] [Zhang X.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 14 ] [Zhang X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 15 ] [Wang F.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 16 ] [Wang F.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 17 ] [Zhuang Q.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 18 ] [Zhuang Q.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 19 ] [Assaraf Y.G.]The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
[ 20 ] [Liu X.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 21 ] [Liu X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 22 ] [Wang Y.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 23 ] [Wang Y.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China
[ 24 ] [Zeng Y.]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 25 ] [Zeng Y.]Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, China

Reprint 's Address：

Email：

Related Keywords：

Type
Departments

All Years Choose Year From to